$121.52−4.33 (−3.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Kymera Therapeutics (KYMR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
44 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 50% below its peak, net margin −794.0%. Worth your attention in FY25: Share count (+76.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼16.7%
39.2
FY21→FY25CAGR −14.3%/yr
Net income ($M)▼39.1%
−311.4
FY21→FY25CAGR —
Free cash flow ($M)▼13.0%
−234.3
FY21→FY25CAGR —
Diluted EPS▼23.8%
−3.69
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+76.1%
48.0mn → 84.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$1.4M
−88.7% YoY in FY25 · 3.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-794¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -794.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 102,236.0 | 39,211.0 | 47,072.0 | 78,592.0 | 46,826.0 | 72,832.0 | ▼16.7% | −14.3% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 72,832.0 | — | — |
Research & development | 429,983.0 | 316,568.0 | 240,248.0 | 189,081.0 | 164,248.0 | 137,017.0 | ▲31.8% | +23.3% |
Selling, general & admin | 77,141.0 | 68,187.0 | 63,534.0 | 55,041.0 | 43,834.0 | 36,345.0 | ▲7.3% | +17.0% |
Total operating expenses | 507,124.0 | 388,610.0 | 308,707.0 | 244,122.0 | 208,082.0 | 173,362.0 | ▲25.9% | +22.4% |
Operating incomefeeds ROC rank | −404,888.0 | −349,399.0 | −261,635.0 | −165,530.0 | −161,256.0 | −100,530.0 | ▼33.5% | — |
Other income, net | 55,463.0 | 38,048.0 | 37,777.0 | 18,568.0 | 6,448.0 | 313.0 | — | — |
Pretax income | −349,425.0 | −311,351.0 | −223,858.0 | −146,962.0 | −154,808.0 | −100,217.0 | ▼39.1% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −349,425.0 | −311,351.0 | −223,858.0 | −146,962.0 | −154,808.0 | −100,217.0 | ▼39.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.63 | −3.69 | −2.98 | −2.52 | −2.87 | −2.09 | ▼23.8% | — |
Diluted shares (mn) | 100.10 | 84.49 | 75.04 | 58.37 | 53.93 | 47.99 | ▲12.6% | +15.2% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | −396.0% | −891.1% | −555.8% | −210.6% | −344.4% | −138.0% | ▼335.3pp | −753.0pp |
Net margin5th pct in Healthcare | −341.8% | −794.0% | −475.6% | −187.0% | −330.6% | −137.6% | ▼318.5pp | −656.4pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Kymera Therapeutics' revenue last fiscal year?
Kymera Therapeutics reported revenue of $39.2M in fiscal 2025, down 16.7% from fiscal 2024.
What was Kymera Therapeutics' net income?
Kymera Therapeutics reported net income of −$311.4M in fiscal 2025, a net margin of −794.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

